GC Cell
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
GC Cell develops living-cell medicines, therapies that use a patient's own or donor cells, modified outside the body, to treat or prevent disease.
Its products and services are used by hospitals, clinics, and research institutions, and it is listed on KOSDAQ, South Korea's technology and small-cap exchange. The business spans five distinct lines: cell therapy development, laboratory specimen-testing services, umbilical-cord-blood banking, bio-logistics, and contract development and manufacturing (CDMO) for other life-science companies.
Summary is AI-generated and may contain errors · figures from DART filings
The filing states that GC Cell acquired its cell-therapy business from Nokchipja (Green Cross) and later expanded into NK- and T-cell therapy, reflecting a deliberate broadening of its therapeutic pipeline.
GC Cell in five facts
What does GC Cell do?
GC Cell develops living-cell medicines, therapies that use a patient's own or donor cells, modified outside the body, to treat or prevent disease.
Where is GC Cell listed and in which sector?
GC Cell (Korean name: 지씨셀) trades under KRX code 144510 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is GC Cell?
Its market capitalisation was US$165.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were GC Cell's latest annual revenue and operating profit?
For fiscal year 2025, GC Cell reported revenue of US$124.9M, an operating loss of US$10.4M and a net loss of US$206.4M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 5.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureSep 15
- Operating results (consolidated) (preliminary) (fair disclosure)
GC Cell filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$29.3M (−3.1% year on year), an operating loss of US$710K and net income of US$1.53M (from a loss a year earlier).
Earnings · Jul 30 - Treasury share disposal: results report
GC Cell Co., Ltd. reports that between July 15 and July 20, 2026 it transferred 73,130 common treasury shares (worth US$661K) directly into employees' individual brokerage accounts, slightly below the 73,203 shares planned due to a change in the number of recipients.
Treasury Shares · Jul 20 - Material event report (treasury share disposal)
GC Cell disclosed a plan to sell treasury shares worth US$752K, about 0.5% of its market value.
Treasury Shares · Jun 30 - Operating results (consolidated) (preliminary) (fair disclosure)
GC Cell filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$25.7M (−5.5% year on year), an operating loss of US$3.52M and a net loss of US$2.02M.
Earnings · May 7 - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
GC Cell updated its previously filed consolidated results for FY2025: revenue of US$112M (−5.1% year on year), an operating loss of US$9.3M and a net loss of US$184M.
Earnings · Mar 9 · 2 versions